A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | MicrobiomeTrials← Back to trialsNCT06406465
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-15Est. Completion: 2027-07-30
Enrollment target: 60 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
MelanomaLi-Fraumeni SyndromePulmonary BlastomaChordomaCongenital Bone Marrow Failure SyndromesCostello SyndromeFanconi AnemiaCFC Syndrome (CFCS)Legius SyndromeRASopathies
Background:
Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer…
Rockville, United StatesEst. completion Jan 1, 2035
Non Small Cell Lung Cancer
Solid Tumor
Rare Cancers
High Grade Glioma
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis…
Scottsdale, United StatesEst. completion Dec 28, 2032